EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use

Myrthe R Naber iD, Mick J M van Eijs, Jildou S Huitema, Jacco J de Haan, Karijn P M Suijkerbuijk, Marijn C Visschedijk, Fiona D M van Schaik

Inflammatory Bowel Diseases · 01.11.2026 · 32 (11) · 2118-2128

DOI: 10.1093/ibd/izag104 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 21.08.2026. Verfasst von Myrthe R Naber und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, Utrecht, 3584 CX, the Nethe…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colitis, Immunosuppressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Immune checkpoint–inhibitor (ICI) colitis is a common adverse event that is primarily treated with corticosteroids but may require selective immunosuppressive therapy (SIT). Although endoscopic features have been associated with SIT use, it remains unclear whether these associations differ by ICI type.

Methods

We conducted a 2-center retrospective cohort study and included patients with histologically confirmed ICI colitis. Endoscopic images were reviewed by gastroenterologists specialized in inflammatory bowel disease (IBD) and scored using the Mayo score and the Immune-Mediated Colitis Endoscopic Score (IMCES). Early SIT use was defined as SIT use within 3 weeks after the start of colitis treatment. Features associated with SIT use were stratified by ICI type, and discriminative performance was evaluated using receiver operating characteristic (ROC) analysis.

Results

Among 255 included patients, 38% required SIT. Biochemical parameters associated with early SIT use were C-reactive protein (CRP) (odds ratio (OR), 1.41; P = .005), and albumin (OR, 0.92; P = .020). Endoscopic features associated with SIT use included erythema (OR, 4.09; P = .006) and exudate (OR, 3.24; P = .012), which were limited to patients treated with anti-cytotoxic T-lymphocyte-associated antigen 4–based (aCTLA-4–based) therapy. In multivariable analysis, ICI type remained the only variable associated with early SIT use (OR, 12.8; P < .001). The IMCES demonstrated areas under the curves (AUCs) of 0.57 (95% CI, 0.50-0.65) for overall and 0.61 (95% CI, 0.53-0.69) for early SIT use.

Conclusions

In patients with ICI colitis, escalation to SIT use was primarily associated with ICI type, with limited additional value of biochemical or endoscopic features. The IMCES showed poor predictive performance in this external validation cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsColitisImmunosuppressive AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedColonoscopyROC CurveAdultAged

Stichwörter der Autor:innen

checkpoint inhibitor–induced colitisendoscopyselective immunosuppressive therapy

Substanzen

Immune Checkpoint InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
  • Department of Oncology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
  • Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.
  • Department of Oncology, University Medical Centre Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.

ORCID-Profile: Myrthe R Naber

Zitieren

APA

Naber, M. R., van Eijs, M. J. M., Huitema, J. S., de Haan, J. J., Suijkerbuijk, K. P. M., Visschedijk, M. C., & van Schaik, F. D. M. (2026). Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use. Inflammatory Bowel Diseases, 32(11), 2118-2128. https://doi.org/10.1093/ibd/izag104

Vancouver

Naber MR, van Eijs MJM, Huitema JS, de Haan JJ, Suijkerbuijk KPM, Visschedijk MC, et al. Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use. Inflammatory Bowel Diseases. 2026;32(11):2118-2128. doi:10.1093/ibd/izag104

BibTeX
@article{Naber2026,
  author = {Naber, Myrthe R and van Eijs, Mick J M and Huitema, Jildou S and de Haan, Jacco J and Suijkerbuijk, Karijn P M and Visschedijk, Marijn C and van Schaik, Fiona D M},
  title = {Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {11},
  pages = {2118--2128},
  doi = {10.1093/ibd/izag104}
}
Kostenlos starten →